Direct oral anticoagulants showed no significant difference in bleeding (OR 0.94), stroke (OR 0.75), or all-cause mortality (OR 0.85) compared to vitamin K antagonists in patients with bioprosthetic valves.
Meta-Analysis (n=4,088)
Do direct oral anticoagulants improve safety and efficacy outcomes compared to vitamin K antagonists in patients with bioprosthetic valves and another indication for anticoagulation?
DOACs appear to be a safe and effective alternative to VKAs in patients with bioprosthetic valves who require anticoagulation for other indications.
Odds Ratio: 0.94 (95% CI 0.56–1.57)
Absolute Event Rate: 16% vs 17%
p-value: p=0.81
Background Direct oral anticoagulants are efficient alternatives to vitamin K antagonists. There is little evidence regarding their use in patients who underwent bioprosthetic valve replacement whether surgically or through a transcatheter approach and have another indication of anticoagulation. Trials have compared different members of the DOACs family to VKAs and showed that they were at least non-inferior to VKAs with regard to safety and efficacy. However, this is still controversial. Our meta-analysis aims at providing a clearer view of their future use in this subgroup of patients. Methods PubMed and Cochrane were searched for randomised clinical trials and observational studies. Bleeding, stroke, and all-cause mortality were the outcomes of interest. Results Ten papers with a total of 4, 088 patients were included. Our meta-analysis revealed no significant differences between the incidence of bleeding between DOACs and warfarin (16% vs. 17%, OR = 0. 94, 95% CI 0. 56–1. 57, p = 0. 81, I 2 = 81%). No statistical difference was found in stroke between both groups (2. 5% vs. 3. 3%, OR = 0. 75, 95% CI 0. 41–1. 38, p = 0. 36, I 2 = 35%). All-cause mortality was not statistically significant between both groups (9. 2% vs. 13. 7%, OR = 0. 85, 95% CI 0. 68–1. 07, p = 0. 16, I 2 = 56%). Interestingly, subgroup analysis of randomised controlled trials and prospective studies favoured DOACs with lower risks of both bleeding and stroke. Conclusion Direct oral anticoagulants appear to be at least as safe and effective as VKAs in patients with bioprosthetic valves and another indication of anticoagulation. There could be potential benefit from the use of DOACs; however, further evidence is required. Systematic Review Registration https: //www. crd. york. ac. uk/prospero/displayᵣecord. php? ID=CRD42021222146, identifier CRD42021222146.
Bakr et al. (2023) conducted a meta-analysis in Bioprosthetic valve replacement with another indication for anticoagulation (n=4,088). Direct oral anticoagulants (DOACs) vs. Vitamin K antagonists (VKAs) was evaluated on Bleeding (OR 0.94, 95% CI 0.56-1.57, p=0.81). Direct oral anticoagulants showed no significant difference in bleeding (OR 0.94), stroke (OR 0.75), or all-cause mortality (OR 0.85) compared to vitamin K antagonists in patients with bioprosthetic valves.